Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells

PURPOSE: Rational targeted therapies are needed for treatment of ovarian cancers. Signaling kinases, Src and MAPK, are activated in high grade serous ovarian cancer (HGSOC). Here, we tested the frequency of activation of both kinases in HGSOC and the therapeutic potential of dual kinase inhibition....

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Simpkins, Fiona, Jang, Kibeom, Yoon, Hyunho, Hew, Karina E., Kim, Minsoon, Azzam, Diana J., Sun, Jun, Zhao, Dekuang, Ince, Tan A., Liu, Wenbin, Guo, Wei, Wei, Zhi, Zhang, Gao, Mills, Gordon B., Slingerland, Joyce M.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557165/
https://ncbi.nlm.nih.gov/pubmed/29959144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3697
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料